Lebovits Chaim

Average Profitability
<0.0001%
Insider Buys Quantity
13
Insider Buys Sum
$283,114.27
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Lebovits Chaim

According to the SEC Form 4 filings, Lebovits Chaim, being in a position of

  1. President & CEO at Brainstorm Cell Therapeutics Inc.,
    оver the last 12 months, has bought 590208 shares for $283,114, and sold 0 shares,
    over all time since 2024-04-17, has bought 590208 shares for $283,114, and sold 0 shares.

The largest purchase of all time was on 2024-04-17 and amounted to 130000 shares of Brainstorm Cell Therapeutics Inc. for $70,941.

Biography of Lebovits Chaim

No biography is available at this moment.

2024-10-01PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
1,836
0.031%
$3.43$6,292-38.46%
2024-09-30PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
22,000
0.0247%
$0.23$5,016-41.16%
2024-05-28PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
15,000
0.0215%
$0.52$7,775-39.29%
2024-05-22PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
25,000
0.0399%
$0.64$16,000-44.29%
2024-05-21PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
25,000
0.0333%
$0.58$14,475-48.55%
2024-05-13PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
10,000
0.0131%
$0.49$4,900-41%
2024-05-11PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
10,000
0.015%
$0.47$4,665-20.07%
2024-05-10PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
20,000
0.0298%
$0.47$9,300-28.95%
2024-05-07PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
66,300
0.0971%
$0.37$24,816-9.78%
2024-05-06PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
135,000
0.1982%
$0.38$50,666-10.7%
2024-04-19PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
15,000
0.0214%
$0.52$7,799-35.84%
2024-04-18PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
115,072
0.172%
$0.53$60,470-33.46%
2024-04-17PurchaseBrainstorm Cell Therapeutics Inc.
BCLI
President & CEO
130,000
0.1919%
$0.55$70,941-36.74%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.